免疫检查点抑制剂相关肺炎的临床诊治建议  

Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor

作　　者：王汉萍[1] 郭潇潇[2] 周佳鑫[3] 段炼[4] 斯晓燕[1] 张丽[5] 李玥[6] 刘小伟[7] 王孟昭[1] 施举红[1] 张力[1] Hanping WANG;Xiaoxiao GUO;Jiaxin ZHOU;Lian DUAN;Xiaoyan SI;Li ZHANG;Yue LI;Xiaowei LIU;Mengzhao WANG;Juhong SHI;Li ZHANG(Department of Respiratory Medicine,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Cardiology,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Rheumatism and Immunology,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Endocrinology,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Clinical Laboratory,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Digestive Medicine,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Ophthalmology,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院,北京协和医院呼吸内科,北京100730 [2]中国医学科学院,北京协和医院心内科,北京100730 [3]中国医学科学院,北京协和医院风湿免疫科,北京100730 [4]中国医学科学院,北京协和医院内分泌科,北京100730 [5]中国医学科学院,北京协和医院检验科,北京100730 [6]中国医学科学院,北京协和医院消化内科,北京100730 [7]中国医学科学院,北京协和医院眼科,北京100730

出　　处：《中国肺癌杂志》2019年第10期621-626,共6页Chinese Journal of Lung Cancer

基　　金：中国医学科学院医学与健康科技创新工程项目（No.2016-I2M-1-002）资助~~

摘　　要：免疫检查点抑制剂在肿瘤中的使用给晚期肿瘤患者带来了新的希望。然而,由免疫检查点抑制剂激活的免疫系统,其中主要是T细胞免疫,可能攻击人体正常组织器官导致相应的免疫毒性反应产生,在肺部可引起免疫检查点抑制剂相关肺炎。这是一类不同于已知肺部间质性肺炎的疾病,如处理不当,有潜在的致命风险。我们将对免疫检查点抑制剂相关肺炎的诊断和治疗给予建议。The increasing use of immunocheckpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immunocheckpoint inhibitors, mainly activated T-cell immunity, may attack normal tissues and organs of the human body and lead to a variety of adverse effects. In the lung, they could induce checkpoint inhibitor associated pneumonitis(CIP). CIP is different from known pulmonary interstitial pneumonitis, and had a potentially fatal risk if it was not being properly treated. We will summarize the characteristics of CIP and give our advice on how to manage immunocheckpoint inhibitor associated pneumonitis.

关 键 词：免疫检查点抑制剂 免疫相关不良反应 检查点抑制剂相关肺炎 

分 类 号：TP3[自动化与计算机技术—计算机科学与技术]